TY  - JOUR
AU  - Kremer, Thomas
AU  - Taylor, Kirsten I.
AU  - Siebourg-Polster, Juliane
AU  - Gerken, Thomas
AU  - Staempfli, Andreas
AU  - Czech, Christian
AU  - Dukart, Juergen
AU  - Galasko, Douglas
AU  - Foroud, Tatiana
AU  - Chahine, Lana M.
AU  - Coffey, Christopher S.
AU  - Simuni, Tanya
AU  - Weintraub, Daniel
AU  - Seibyl, John
AU  - Poston, Kathleen L.
AU  - Toga, Arthur W.
AU  - Tanner, Caroline M.
AU  - Marek, Kenneth
AU  - Hutten, Samantha J.
AU  - Dziadek, Sebastian
AU  - Trenkwalder, Claudia
AU  - Pagano, Gennaro
AU  - Mollenhauer, Brit
TI  - Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
JO  - Movement disorders
VL  - 36
IS  - 8
SN  - 1531-8257
CY  - New York, NY
PB  - Wiley
M1  - FZJ-2021-02085
SP  - 1972-1978
PY  - 2021
AB  - Background: Cerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD).Objective: The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis.Methods: Absolute levels of multiple monoamine metabolites in CSF were quantified by liquid chromatography coupled with tandem mass spectrometry from 161 individuals with early PD and 115 HCs from the Parkinson's Progression Marker Initiative and de novo PD (DeNoPA) studies.Results: Baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with HCs. HVA levels correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale total scores (P < 0.01). Both HVA/dopamine and DOPAC/dopamine levels correlated with caudate nucleus and raw DOPAC with putamen dopamine transporter single-photon emission computed tomography uptake ratios (P < 0.01). No metabolite changed over 2 years in drug-naive individuals, but some changed on starting levodopa treatment.Conclusions: HVA and DOPAC CSF levels mirrored nigrostriatal pathway damage, confirming the central role of dopaminergic degeneration in early PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords: CSF; Parkinson's disease; biomarker; catecholamine; homovanillic acid; monoamine metabolites; neurotransmitter.
LB  - PUB:(DE-HGF)16
C6  - pmid:33942926
UR  - <Go to ISI:>//WOS:000646650300001
DO  - DOI:10.1002/mds.28608
UR  - https://juser.fz-juelich.de/record/892447
ER  -